WMK

In the past six months, WMK's stock was influenced by its Q1 2026 results, which showed a 4.6% revenue increase and a 42.5% net income increase, and a subsequent quarterly dividend announcement. Q2 2026 results reported a 4.6% revenue increase but a 9.6% net income decrease, partly due to the Inflation Reduction Act's impact on pharmacy revenue and increased operating expenses. The stock declined about 5% since June 30, 2026, also affected by broader market weakness in consumer staples.